Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Dopamine-replacing gene therapy for Parkinson’s disease: biochemical background and current clinical experience. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1177/1877718x261459875
10.1177/1877718x261459875 · External reference
10.1038/s41582-026-01183-1
10.1038/s41582-026-01183-1 · External reference
10.1007/s00702-025-03088-7
10.1007/s00702-025-03088-7 · External reference
10.1016/j.neurop.2024.100153
10.1016/j.neurop.2024.100153 · External reference
10.1016/j.neurop.2024.100147
10.1016/j.neurop.2024.100147 · External reference
10.1038/s41531-023-00533-w
10.1038/s41531-023-00533-w · External reference
10.1016/j.ymthe.2025.12.011
10.1016/j.ymthe.2025.12.011 · External reference
10.1038/s41583-024-00812-2
10.1038/s41583-024-00812-2 · External reference
10.1212/wnl.0000000000218226
10.1212/wnl.0000000000218226 · External reference
10.1007/s00702-023-02673-y
10.1007/s00702-023-02673-y · External reference
10.1002/ana.78257
10.1002/ana.78257 · External reference
Motor complications in Parkinson’s disease: results from 3343 patients followed for up to 12 years
10.1002/mdc3.14044 · 2024 · External reference
10.1186/1471-2377-11-35
10.1186/1471-2377-11-35 · External reference
10.1093/brain/awt192
10.1093/brain/awt192 · External reference
10.1055/s-0037-1602423
10.1055/s-0037-1602423 · External reference
10.1093/brain/awag002
10.1093/brain/awag002 · External reference
Pharmacological insights into levodopa-induced motor fluctuations in patients with Parkinson’s disease
10.1002/mdc3.12389 · 2016 · External reference
Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson’s disease: a randomised, controlled, double-blind, double-dummy study
10.1016/s1474-4422(13)70293-x · 2014 · External reference
Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson’s disease: a randomised, double-blind, active-controlled, phase 3 trial
10.1016/s1474-4422(22)00400-8 · 2022 · External reference
10.3390/jcm12134427
10.3390/jcm12134427 · External reference
10.1038/s41582-019-0145-9
10.1038/s41582-019-0145-9 · External reference
10.1001/jamaneurol.2025.3373
10.1001/jamaneurol.2025.3373 · External reference
10.1016/s0021-9258(18)93832-9
10.1016/s0021-9258(18)93832-9 · External reference
10.1016/0003-9861(63)90003-1
10.1016/0003-9861(63)90003-1 · External reference
10.1021/bi980582l
10.1021/bi980582l · External reference
10.1021/bi052283j
10.1021/bi052283j · External reference
10.1007/s00726-007-0547-7
10.1007/s00726-007-0547-7 · External reference
10.1002/tcr.20166
10.1002/tcr.20166 · External reference
10.1046/j.1432-1033.2003.03933.x
10.1046/j.1432-1033.2003.03933.x · External reference
10.1007/bf01281153
10.1007/bf01281153 · External reference
10.1126/science.6117945
10.1126/science.6117945 · External reference
10.1126/science.276.5310.248
10.1126/science.276.5310.248 · External reference
10.1523/jneurosci.3910-09.2009
10.1523/jneurosci.3910-09.2009 · External reference
10.1073/pnas.0511153103
10.1073/pnas.0511153103 · External reference
10.1046/j.1471-4159.2001.00181.x
10.1046/j.1471-4159.2001.00181.x · External reference
10.1093/oxfordjournals.jbchem.a122386
10.1093/oxfordjournals.jbchem.a122386 · External reference
10.3390/ijms21031170
10.3390/ijms21031170 · External reference
10.3389/fphys.2025.1618330
10.3389/fphys.2025.1618330 · External reference
10.1016/j.bbrc.2004.01.068
10.1016/j.bbrc.2004.01.068 · External reference
10.1016/j.abb.2010.12.017
10.1016/j.abb.2010.12.017 · External reference
10.1111/jnc.14675
10.1111/jnc.14675 · External reference
10.1021/bi9914255
10.1021/bi9914255 · External reference
10.1016/j.bbrc.2005.07.183
10.1016/j.bbrc.2005.07.183 · External reference
10.1126/science.aam9080
10.1126/science.aam9080 · External reference
10.3390/antiox12040955
10.3390/antiox12040955 · External reference
Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson’s disease: implications for pathogenesis and therapy
10.1073/pnas.97.2.571 · 2000 · External reference
10.1007/s00702-019-02106-9
10.1007/s00702-019-02106-9 · External reference
Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in parkinson disease
10.1038/nm0602-600 · 2002 · External reference
Protective and toxic roles of dopamine in Parkinson’s disease
10.1111/jnc.12686 · 2014 · External reference
10.1038/s41591-026-04436-0
10.1038/s41591-026-04436-0 · External reference
10.1021/bi010546d
10.1021/bi010546d · External reference
10.1038/nsb0797-578
10.1038/nsb0797-578 · External reference
10.1038/s41467-021-27657-y
10.1038/s41467-021-27657-y · External reference
10.1016/s0006-291x(88)80524-2
10.1016/s0006-291x(88)80524-2 · External reference
10.1074/jbc.m102237200
10.1074/jbc.m102237200 · External reference
A brain-specific decrease of the tyrosine hydroxylase protein in sepiapterin reductase-null mice–as a mouse model for Parkinson’s disease
10.1016/j.bbrc.2008.01.028 · 2008 · External reference
10.1016/j.bbrc.2025.153129
10.1016/j.bbrc.2025.153129 · External reference
10.1038/s41380-024-02608-3
10.1038/s41380-024-02608-3 · External reference
10.1016/0166-2236(89)90074-x
10.1016/0166-2236(89)90074-x · External reference
10.1016/0166-2236(90)90110-v
10.1016/0166-2236(90)90110-v · External reference
10.1016/j.neuron.2015.08.039
10.1016/j.neuron.2015.08.039 · External reference
10.1016/j.neuron.2024.12.013
10.1016/j.neuron.2024.12.013 · External reference
10.1146/annurev-neuro-071013-013916
10.1146/annurev-neuro-071013-013916 · External reference
10.1016/0306-4522(89)90168-1
10.1016/0306-4522(89)90168-1 · External reference
10.1086/321970
10.1086/321970 · External reference
10.1042/bj20110293
10.1042/bj20110293 · External reference
Molecular and metabolic bases of tetrahydrobiopterin (BH(4)) deficiencies
10.1016/j.ymgme.2021.04.003 · 2021 · External reference
10.1016/j.ymgme.2011.08.017
10.1016/j.ymgme.2011.08.017 · External reference
10.1038/ng1194-236
10.1038/ng1194-236 · External reference
10.1080/14737175.2026.2647033
10.1080/14737175.2026.2647033 · External reference
10.1080/14712598.2024.2386339
10.1080/14712598.2024.2386339 · External reference
Gene therapy for Parkinson’s disease-ample room for optimism
10.1016/j.conb.2025.103150 · 2026 · External reference
10.1007/s00415-025-12940-5
10.1007/s00415-025-12940-5 · External reference
10.1016/j.ymthe.2025.03.030
10.1016/j.ymthe.2025.03.030 · External reference
10.1212/wnl.0000000000012952
10.1212/wnl.0000000000012952 · External reference
10.1212/wnl.0b013e3181c29356
10.1212/wnl.0b013e3181c29356 · External reference
A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson’s disease
10.1038/mt.2010.135 · 2010 · External reference
10.1002/mds.70378
10.1002/mds.70378 · External reference
Post-mortem studies of neurturin gene therapy for Parkinson’s disease: two subjects with 10 years CERE120 delivery
10.1002/mds.29518 · 2023 · External reference
Intraputaminal delivery of adeno-associated virus serotype 2-glial cell Line-derived neurotrophic factor in mild or moderate Parkinson’s disease
10.1002/mds.30193 · 2025 · External reference
10.1016/j.omta.2026.201779
10.1016/j.omta.2026.201779 · External reference
10.1186/s40478-026-02294-y
10.1186/s40478-026-02294-y · External reference
Artificial miRNA-mediated reduction of SNCA for the treatment of alpha-synucleinopathies
10.1016/j.ymthe.2025.11.017 · 2026 · External reference
Disease-modifying, multidimensional efficacy of putaminal Ca(V)1.3-shRNA gene therapy in aged parkinsonism male and female macaques
10.1016/j.ymthe.2025.05.027 · 2025 · External reference
10.3390/cells11233822
10.3390/cells11233822 · External reference
10.1038/s41598-025-34908-1
10.1038/s41598-025-34908-1 · External reference
10.1038/s41573-019-0012-9
10.1038/s41573-019-0012-9 · External reference
Adeno-associated virus gene delivery to hard-to-transduce tissues: biological barriers, engineering strategies, and clinical challenges
2026 · External reference
Unresolved reference
2021 · External reference
Persistent expression of dopamine-synthesizing enzymes 15 years after gene transfer in a primate model of Parkinson’s disease
10.1089/humc.2017.010 · 2017 · External reference
10.1056/nejmoa2601608
10.1056/nejmoa2601608 · External reference
10.1016/j.ymthe.2025.04.045
10.1016/j.ymthe.2025.04.045 · External reference
10.1016/j.ymthe.2023.10.015
10.1016/j.ymthe.2023.10.015 · External reference
Death after high-dose rAAV9 gene therapy in a patient with Duchenne’s muscular dystrophy
2023 · External reference
10.1016/j.ijcard.2023.131704
10.1016/j.ijcard.2023.131704 · External reference
10.1177/10430342251378524
10.1177/10430342251378524 · External reference
10.1002/jmv.23818
10.1002/jmv.23818 · External reference
10.3389/fimmu.2024.1450858
10.3389/fimmu.2024.1450858 · External reference
10.2174/1566523221666210922155413
10.2174/1566523221666210922155413 · External reference
10.1089/hum.2022.170
10.1089/hum.2022.170 · External reference
10.1016/j.omtm.2025.101420
10.1016/j.omtm.2025.101420 · External reference
10.1523/jneurosci.22-23-10302.2002
10.1523/jneurosci.22-23-10302.2002 · External reference
10.1167/iovs.13-11871
10.1167/iovs.13-11871 · External reference
10.1002/ana.10189
10.1002/ana.10189 · External reference
10.1212/wnl.54.10.1910
10.1212/wnl.54.10.1910 · External reference
Widespread AAV1- and AAV2-mediated transgene expression in the nonhuman primate brain: implications for Huntington’s disease
10.1038/mtm.2016.37 · 2016 · External reference
10.1038/s41467-023-40436-1
10.1038/s41467-023-40436-1 · External reference
Behavioral recovery in a primate model of Parkinson’s disease by triple transduction of striatal cells with adeno-associated viral vectors expressing dopamine-synthesizing enzymes
10.1089/10430340252792486 · 2002 · External reference
10.1006/mthe.2001.0466
10.1006/mthe.2001.0466 · External reference
Unresolved reference
External reference
10.1002/mds.70422
10.1002/mds.70422 · External reference
10.1002/mdc3.13685
10.1002/mdc3.13685 · External reference
10.1126/scitranslmed.3003640
10.1126/scitranslmed.3003640 · External reference
10.1093/brain/awy331
10.1093/brain/awy331 · External reference
10.1093/braincomms/fcab078
10.1093/braincomms/fcab078 · External reference
10.1038/s41467-021-24524-8
10.1038/s41467-021-24524-8 · External reference
10.1016/j.ymthe.2021.11.005
10.1016/j.ymthe.2021.11.005 · External reference
10.1016/j.ymgme.2023.107624
10.1016/j.ymgme.2023.107624 · External reference
Eladocagene Exuparvovec: first approval
2022 · External reference
10.1016/j.clinthera.2024.12.008
10.1016/j.clinthera.2024.12.008 · External reference
10.1007/s00381-025-07020-y
10.1007/s00381-025-07020-y · External reference
10.1177/1877718x251352416
10.1177/1877718x251352416 · External reference
10.1007/s00702-026-03205-0
10.1007/s00702-026-03205-0 · External reference
10.1007/s40120-025-00764-4
10.1007/s40120-025-00764-4 · External reference
Triple transduction with adeno-associated virus vectors expressing tyrosine hydroxylase, aromatic L-amino acid decarboxylase, and GTP cyclohydrolase I for gene therapy of Parkinson’s disease
10.1089/10430340050083243 · 2000 · External reference
Optimizing transgene configuration and protein fusions to maximize dopamine production for the gene therapy of Parkinson’s disease
10.1089/humc.2016.056 · 2016 · External reference
Long-term follow-up of a phase I/II study of ProSavin, a lentiviral vector gene therapy for Parkinson’s disease
10.1089/humc.2018.081 · 2018 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Calibration of unified Parkinson’s disease rating scale scores to movement disorder society-unified Parkinson’s disease rating scale scores
10.1002/mds.25122 · 2012 · External reference
10.1093/stmcls/sxae042
10.1093/stmcls/sxae042 · External reference
10.1038/d41591-025-00036-6
10.1038/d41591-025-00036-6 · External reference
10.1038/s41586-025-08700-0
10.1038/s41586-025-08700-0 · External reference
10.1038/s41586-025-08845-y
10.1038/s41586-025-08845-y · External reference
10.1038/nm1747
10.1038/nm1747 · External reference
10.1038/nm1746
10.1038/nm1746 · External reference
10.1038/nm1752
10.1038/nm1752 · External reference
10.3390/cells14161248
10.3390/cells14161248 · External reference
10.1177/15353702231198078
10.1177/15353702231198078 · External reference
10.1038/s41531-021-00189-4
10.1038/s41531-021-00189-4 · External reference
